{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:37:05Z","timestamp":1790980625053,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204419"],"award-info":[{"award-number":["204419"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204419"],"award-info":[{"award-number":["204419"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204419"],"award-info":[{"award-number":["204419"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Epstein-Barr virus (EBV) is one of the most common human viruses and the cause of pathologies such as infectious mononucleosis (IM) and certain cancers. No vaccine against EBV infection currently exists, but such vaccines are in development. Knowledge of how EBV is transmitted at the population level is critical to the development of target product profiles (TPPs) for such vaccines and future vaccination strategies. We present the first mathematical model of EBV transmission, parameterised using data from England, and use it to compare hypothetical prophylactic vaccines with different characteristics and the impact of vaccinating different age groups. We found that vaccine duration had more impact than vaccine efficacy on modelled EBV and IM prevalence. The age group vaccinated also had an important effect: vaccinating at a younger age led to a greater reduction in seroprevalence but an increase in IM cases associated with delayed infection. Vaccination had impact on cancer incidence only in the long run, because in England most EBV-related cancers arise in later life. Durability of protection should be a key factor to prioritise in EBV vaccine development and included in vaccine TPPs. These findings are timely and important for vaccine developers and policy-makers alike.<\/jats:p>","DOI":"10.1038\/s41598-019-45381-y","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T10:02:56Z","timestamp":1561543376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Modelling the dynamics of EBV transmission to inform a vaccine target product profile and future vaccination strategy"],"prefix":"10.1038","volume":"9","author":[{"given":"Lara","family":"Gosc\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne R.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham S.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna E. A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen R.","family":"Stagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"key":"45381_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2613.2001.iep190.x","volume":"82","author":"G Niedobitek","year":"2001","unstructured":"Niedobitek, G., Meru, N. & Delecluse, H.-J. Epstein-barr virus infection and human malignancies. Int. journal of experimental pathology 82, 149\u2013170 (2001).","journal-title":"Int. journal of experimental pathology"},{"key":"45381_CR2","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1038\/emm.2014.82","volume":"47","author":"CY Ok","year":"2015","unstructured":"Ok, C. Y., Li, L. & Young, K. H. Ebv-driven b-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp. & molecular medicine 47, e132 (2015).","journal-title":"Exp. & molecular medicine"},{"key":"45381_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ijc.2910220304","volume":"22","author":"RJ Biggar","year":"1978","unstructured":"Biggar, R. J. et al. Primary epstein-barr virus infections in african infants. i. decline of maternal antibodies and time of infection. Int. journal of cancer 22, 239\u2013243 (1978).","journal-title":"Int. journal of cancer"},{"key":"45381_CR4","unstructured":"Winter, J. et al. Predictors of epstein-barr virus serostatus and implications for vaccine policy: An observational study and review of the literature. (Under submission)."},{"key":"45381_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.virusres.2009.07.005","volume":"143","author":"CM Chang","year":"2009","unstructured":"Chang, C. M., Kelly, J. Y., Mbulaiteye, S. M., Hildesheim, A. & Bhatia, K. The extent of genetic diversity of epstein-barr virus and its geographic and disease patterns: a need for reappraisal. Virus research 143, 209\u2013221 (2009).","journal-title":"Virus research"},{"key":"45381_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1634\/theoncologist.2008-0036","volume":"13","author":"A Carbone","year":"2008","unstructured":"Carbone, A., Gloghini, A. & Dotti, G. Ebv-associated lymphoproliferative disorders: classification and treatment. The oncologist 13, 577\u2013585 (2008).","journal-title":"The oncologist"},{"key":"45381_CR7","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1158\/0008-5472.CAN-06-3566","volume":"67","author":"H Hjalgrim","year":"2007","unstructured":"Hjalgrim, H. et al. Infectious mononucleosis, childhood social environment, and risk of hodgkin lymphoma. Cancer research 67, 2382\u20132388 (2007).","journal-title":"Cancer research"},{"key":"45381_CR8","doi-asserted-by":"publisher","first-page":"13204","DOI":"10.1056\/NEJMoa023141","volume":"349","author":"H Hjalgrim","year":"2003","unstructured":"Hjalgrim, H. et al. Characteristics of hodgkin\u2019s lymphoma after infectious mononucleosis. New Engl. J. Medicine 349, 13204\u20131332 (2003).","journal-title":"New Engl. J. Medicine"},{"key":"45381_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young, L. S. & Rickinson, A. B. Epstein\u2013barr virus: 40 years on. Nature Reviews Cancer 4, 757 (2004).","journal-title":"Nature Reviews Cancer"},{"issue":"4","key":"45381_CR10","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1038\/cti.2015.4","volume":"4","author":"Jeffrey I Cohen","year":"2015","unstructured":"Cohen, J. I. Epstein\u2013barr virus vaccines. Clinical & translational immunology 4 (2015).","journal-title":"Clinical & Translational Immunology"},{"key":"45381_CR11","doi-asserted-by":"publisher","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","volume":"3","author":"JI Cohen","year":"2011","unstructured":"Cohen, J. I., Fauci, A. S., Varmus, H. & Nabel, G. J. Epstein-barr virus: an important vaccine target for cancer prevention. Sci. translational medicine 3, 107fs7\u2013107fs7 (2011).","journal-title":"Sci. translational medicine"},{"key":"45381_CR12","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo, M. et al. Rational design of an epstein-barr virus vaccine targeting the receptor-binding site. Cell 162, 1090\u20131100 (2015).","journal-title":"Cell"},{"key":"45381_CR13","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1038\/d41586-018-07366-1","volume":"563","author":"C Ainsworth","year":"2018","unstructured":"Ainsworth, C. Building a better lymphoma vaccine. Nature 563, S52 (2018).","journal-title":"Nature"},{"key":"45381_CR14","unstructured":"CDC. Varicella vaccine effectiveness and duration of protection. figshare https:\/\/www.cdc.gov\/vaccines\/vpd-vac\/varicella\/hcp-effective-duration.htm (last accessed December 2017)."},{"key":"45381_CR15","first-page":"700","volume":"115","author":"WO Kermack","year":"1927","unstructured":"Kermack, W. O. & McKendrick, A. G. A contribution to the mathematical theory of epidemics. Proceedings of the royal society of london. Series A, Containing papers of a mathematical and physical character 115, 700\u2013721 (1927).","journal-title":"Proceedings of the royal society of london. Series A, Containing papers of a mathematical and physical character"},{"key":"45381_CR16","unstructured":"HSE. Health survey for england. figshare https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england (last accessed December 2017)."},{"key":"45381_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2319-7","volume":"17","author":"L Pembrey","year":"2017","unstructured":"Pembrey, L. et al. Cytomegalovirus, epstein-barr virus and varicella zoster virus infection in the first two years of life: a cohort study in bradford, uk. BMC infectious diseases 17, 220 (2017).","journal-title":"BMC infectious diseases"},{"key":"45381_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0163-4453(80)90770-7","volume":"2","author":"I Kessell","year":"1980","unstructured":"Kessell, I. et al. Epstein-barr virus infection in children entering a paediatric unit. J. Infect. 2, 269\u2013274 (1980).","journal-title":"J. Infect."},{"key":"45381_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1086\/505400","volume":"43","author":"DH Crawford","year":"2006","unstructured":"Crawford, D. H. et al. A cohort study among university students: identification of risk factors for epstein-barr virus seroconversion and infectious mononucleosis. Clin. infectious diseases 43, 276\u2013282 (2006).","journal-title":"Clin. infectious diseases"},{"key":"45381_CR20","unstructured":"ONS. Office for national statistics. figshare https:\/\/www.ons.gov.uk\/ (date last accessed December 2017)."},{"key":"45381_CR21","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1099\/vir.0.011866-0","volume":"90","author":"FH Leendertz","year":"2009","unstructured":"Leendertz, F. H. et al. Novel cytomegaloviruses in free-ranging and captive great apes: phylogenetic evidence for bidirectional horizontal transmission. J. Gen. Virol. 90, 2386\u20132394 (2009).","journal-title":"J. Gen. Virol."},{"key":"45381_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-151","volume":"14","author":"E Visser","year":"2014","unstructured":"Visser, E. et al. The epidemiology of infectious mononucleosis in northern scotland: a decreasing incidence and winter peak. BMC infectious diseases 14, 151 (2014).","journal-title":"BMC infectious diseases"},{"key":"45381_CR23","unstructured":"CRUK. Statistics by cancer type. figshare http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type (last accessed 2017)."},{"key":"45381_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.beha.2012.01.005","volume":"25","author":"M Roschewski","year":"2012","unstructured":"Roschewski, M. & Wilson, W. H. Ebv-associated lymphomas in adults. Best Pract. & Res. Clin 25, 75\u201389 (2012).","journal-title":"Best Pract. & Res. Clin"},{"key":"45381_CR25","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1182\/blood-2005-01-0168","volume":"106","author":"C Bellan","year":"2005","unstructured":"Bellan, C. et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for ebv-positive and ebv-negative burkitt lymphomas. Blood 106, 1031\u20131036 (2005).","journal-title":"Blood"},{"key":"45381_CR26","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1093\/annonc\/7.suppl_4.S5","volume":"7","author":"A Jarrett","year":"1996","unstructured":"Jarrett, A., Armstrong, A. & Alexander, E. Epidemiology of ebv and hodgkin\u2019s lymphoma. Annals of oncology 7, S5\u2013S10 (1996).","journal-title":"Annals of oncology"},{"issue":"4","key":"45381_CR27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/jnci\/56.4.697","volume":"56","author":"M.A. Epstein","year":"1976","unstructured":"Epstein, M. Epstein-barr virus\u2014is it time to develop a vaccine program? (1976).","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"45381_CR28","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.291.7.851","volume":"291","author":"M V\u00e1zquez","year":"2004","unstructured":"V\u00e1zquez, M. et al. Effectiveness over time of varicella vaccine. Jama 291, 851\u2013855 (2004).","journal-title":"Jama"},{"key":"45381_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","volume":"23","author":"B Kuter","year":"2004","unstructured":"Kuter, B. et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. The Pediatric infectious disease journal 23, 132\u2013137 (2004).","journal-title":"The Pediatric infectious disease journal"},{"key":"45381_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/pgmj.2005.038984","volume":"82","author":"P Welsby","year":"2006","unstructured":"Welsby, P. Chickenpox, chickenpox vaccination, and shingles. Postgraduate medical journal 82, 351\u2013352 (2006).","journal-title":"Postgraduate medical journal"},{"key":"45381_CR31","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/jnci\/92.18.1522","volume":"92","author":"H Hjalgrim","year":"2000","unstructured":"Hjalgrim, H. et al. Risk of hodgkin\u2019s disease and other cancers after infectious mononucleosis. J. Natl. Cancer Inst. 92, 1522\u20131528 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"45381_CR32","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/S0140-6736(01)06961-6","volume":"358","author":"PD White","year":"2001","unstructured":"White, P. D. et al. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. The Lancet 358, 1946\u20131954 (2001).","journal-title":"The Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45381-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45381-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45381-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:58:15Z","timestamp":1671274695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-45381-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["45381"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-45381-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]},"assertion":[{"value":"16 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9290"}}